Eli Lilly: target ranges raised for 2024
For the first three months of 2024, the pharmaceutical company posted a 59% increase in adjusted EPS (non-GAAP) to $2.58, including $0.10 in acquired intellectual property charges.
At $8.77 billion, sales were up 26% (of which 10% in volume growth and 16% in price increases), driven by its flagship drugs Mounjaro, Zepbound, Verzenio and Jardiance.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction